Walleye Capital’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Walleye Capital’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-72,784	Closed	-$733K	–	4611
2022 Q4	$733K	Hold	72,784	–	–	0.01%	1195
2022 Q3	$721K	Hold	72,784	–	–	0.01%	1191
2022 Q2	$710K	Hold	72,784	–	–	0.02%	821
2022 Q1	$717K	Sell	72,784 -2,417	-3%	-$23.9K	0.02%	809
2021 Q4	$745K	Hold	75,201	–	–	0.02%	750
2021 Q3	$747	Hold	75,201	–	–	0.02%	590
2021 Q2	$751	Buy	75,201 +201	+0.3%	+$2.01K	0.03%	569
2021 Q1	$755	Buy	+75,000	New	+$749K	0.04%	397

Walleye Capital's EBACU Position: Q1 2023 in Review

Walleye Capital sold out of European Biotech Acquisition Corp. Units (EBACU) in Q1 2023, closing a stake of 72,784 shares — an estimated $733K sold.

Walleye Capital first reported a position in EBACU in Q1 2021 and held it in 8 quarters. The position peaked at $745K in Q4 2021. 0 funds tracked by Wall St. Rank hold EBACU as of Q1 2023.

Walleye Capital reported no remaining European Biotech Acquisition Corp. Units position as of Q1 2023 after selling out during the quarter.
Walleye Capital sold 72,784 European Biotech Acquisition Corp. Units shares in Q1 2023, an estimated $733K.
Walleye Capital first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 8 quarters.
Walleye Capital's European Biotech Acquisition Corp. Units position peaked at $745K in Q4 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.